DOCSLIB.ORG

A61p25/06 (2006.01) A61p25/22 (2006.01)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A61p25/06 (2006.01) A61p25/22 (2006.01) ) ( (51) International Patent Classification: 62/835,485 17 April 2019 (17.04.2019) US A61K 31/4045 (2006.01) A61P25/06 (2006.01) 62/893, 110 28 August 2019 (28.08.2019) US A61K 31/675 (2006.01) A61P25/22 (2006.01) 62/893,61 1 29 August 2019 (29.08.2019) US A61P 25/00 (2006.01) 62/946, 159 10 December 2019 (10. 12.2019) US (21) International Application Number: (71) Applicant: COMPASS PATHFINDER LIMITED PCT/IB2020/053687 [GB/GB]; 3rd Floor, 1 Ashley Road, Altrincham, Cheshire WA14 2DT (GB). (22) International Filing Date: 17 April 2020 (17.04.2020) (72) Inventors: LONDESBROUGH, Derek John; 37 Linden Grove, Hartlepool, Durham TS26 9QA (GB). BROWN, (25) Filing Language: English Christopher; 30 Cherrytree Gardens, Gateshead, Tyne and (26) Publication Language: English Wear NE9 6TY (GB). NORTHEN, Julian Scott; 36 Hep- scott Terrace, South Shields, Tyne and Wear NE33 4TH (30) Priority Data: (GB). MOORE, Gillian; 22 Matfen Court, Sedgefield, 62/835,449 17 April 2019 (17.04.2019) US Durham TS21 2JB (GB). PATIL, Hemant Kashinath; 62/835,450 17 April 2019 (17.04.2019) US 137C Kingston Road, Leatherhead, Surrey KT22 7NT 62/835,458 17 April 2019 (17.04.2019) US (GB). NICHOLS, David E.; 56702 Nash, Chapel Hill, NC 62/835,460 17 April 2019 (17.04.2019) US 27517 (US). CROAL, Megan; c/o COMPASS Pathways 62/835,464 17 April 2019 (17.04.2019) US Limited, 3rd Floor, 1 Ashley Road, Altrincham Cheshire 62/835,465 17 April 2019 (17.04.2019) US WA14 2DT (GB). ERIKSSON, Hans Ake; c/o COM¬ 62/835,472 17 April 2019 (17.04.2019) US PASS Pathways Limited, 3rd Floor, 1 Ashley Road, Altrin¬ 62/835,474 17 April 2019 (17.04.2019) US cham Cheshire WA14 2DT (GB). GOLDSMITH, George; 62/835,476 17 April 2019 (17.04.2019) US c/o COMPASS Pathways Limited, 3rd Floor, 1 Ashley 62/835,477 17 April 2019 (17.04.2019) US Road, Altrincham Cheshire WA14 2DT (GB). HICKEY, 62/835,478 17 April 2019 (17.04.2019) US Molly Tabitha; c/o COMPASS Pathways Limited, 3rd 62/835,479 17 April 2019 (17.04.2019) US Floor, 1 Ashley Road, Altrincham Cheshire WA14 2DT 62/835,480 17 April 2019 (17.04.2019) US (GB). HURLEY, Shaun; c/o COMPASS Pathways Limit¬ 62/835,481 17 April 2019 (17.04.2019) US ed, 3rd Floor, 1 Ashley Road, Altrincham Cheshire WA14 62/835,482 17 April 2019 (17.04.2019) US 2DT (GB). MALIEVSKAIA, Ekaterina; c/o COMPASS 62/835,484 17 April 2019 (17.04.2019) US (54) Title: METHODS FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN Exact Mass: 284 9 id. : 284 25 (57) Abstract: The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a thera¬ peutically -effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and condi¬ tions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders. [Continued on nextpage] \ ( > 2020 2 12 5 1 VI ||||| |||| | III |||||| |||||| I III || |||| |||| |||| III Mill Pathways Limited, 3rd Floor, 1 Ashley Road, Altrincham Cheshire WA14 2DT (GB). MARWOOD, Lindsey; c/o COMPASS Pathways Limited, 3rd Floor, 1 Ashley Road, Altrincham Cheshire WA14 2DT (GB). MCCULLOCH, Drummond E-Wen Joe; c/o COMPASS Pathways Limit¬ ed, 3rd Floor, 1 Ashley Road, Altrincham Cheshire WA14 2DT (GB). MEDHURST, Laurie Emma; c/o COMPASS Pathways Limited, 3rd Floor, 1 Ashley Road, Altrin¬ cham Cheshire WA14 2DT (GB). POULSEN, Nathan; c/o COMPASS Pathways Limited, 3rd Floor, 1 Ashley Road, Altrinch a m Cheshire WA14 2DT (GB). SELIMBE- YOGLU, Aslihan; c/o COMPASS Pathways Limited, 3rd Floor, 1 Ashley Road, Altrincham Cheshire WA14 2DT (GB). SOULA, A na 's: c/o COMPASS Pathways Limit¬ ed, 3rd Floor, 1 Ashley Road, Altrincham Cheshire WA14 2DT (GB). SHUXIANG, Amanda Tan; c/o COMPASS Pathways Limited, 3rd Floor, 1 Ashley Road, Altrincham Cheshire WA14 2DT (GB). VERAART, Manon Cecile Elisabeth; c/o COMPASS Pathways Limited, 3rd Floor, 1 Ashley Road, Altrincham Cheshire WA14 2DT (GB). WHELAN, Tobias Patrick; c/o COMPASS Pathways Limited, 3rd Floor, 1 Ashley Road, Altrincham Cheshire WA14 2DT (GB). WILDE, Lars Christian; c/o COM¬ PASS Pathways Limited, 3rd Floor, 1 Ashley Road, Altrin¬ cham Cheshire WA14 2DT (GB). WRIGHT, Stephen; c/ o COMPASS Pathways Limited, 3rd Floor, 1 Ashley Road, Altrincham Cheshire WA14 2DT (GB). (74) Agent: COOLEY (UK) LLP; Dashwood, 6 9 Old Broad Street, London EC2M IQS (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, A Z , BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available) : ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE METHODS FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN RELATED APPLICATIONS This application claims priority to and benefit of U.S. Application Serial Nos. 62/835,449; 62/835,450; 62/835,458; 62/835,460; 62/835,464; 62/835,465; 62/835,472; 62/835,474; 62/835,476; 62/835,477; 62/835,478; 62/835,479; 62/835,480; 62/835,481 ; 62/835,482; 62/835,484; and 62/835,485, all filed April 17, 2019; U.S. Application Serial No. 62/893,1 10, filed August 28, 2019, U.S. Application Serial No. 62/893,61 1, filed August 29, 2019, and U.S. Application Serial No. 62/946,159, filed December 10, 2019, each of which is incorporated herein by reference in its entirety. BACKGROUND Psilocybin belongs to a class of drugs referred to as psychedelics (“mind-manifesting” drugs). Specifically, psilocybin is considered a 5-hydroxytryptaminergic (serotonergic) psychedelic, as distinguished from other tryptamines such as dimethyltryptamine (DMT), ergolines such as lysergic acid diethylamide (LSD), and phenethylamines such as mescaline. Psilocybin was first isolated from psilocybe mushrooms and later synthesized in a laboratory. There are several common diseases, disorders, and conditions for which no adequate treatment, therapies or cure exist, including: • Anxiety Disorders: Anxiety disorders are a class of psychiatric disorders that involve extreme fear or worry. Oftentimes, anxiety disorders interfere with daily activities, such as job performance, school work, and relationships. Anxiety disorders have a variety of causes, including changes in the brain, environmental stress, and genetics. Examples of anxiety disorders include acute stress disorder, anxiety due to a medical condition, generalized anxiety disorder, panic disorder, panic attack, a phobia, post-traumatic stress disorder, obsessive-compulsive disorder, separation anxiety disorder, social anxiety disorder, substance-induced anxiety disorder, and selective mutism. • Headache Disorders: Headache disorders are characterized by recurrent headaches and are among the most common disorders of the nervous system. Headaches are a disabling feature of headache disorders, such as migraine, tension-type headache, and cluster headaches. • Eating Disorders: Eating disorders are characterized by irregular eating habits and severe distress or concern about body weight or shape. Eating disturbances may include inadequate or excessive food intake which can ultimately damage an individual’s physical and/or psychological health. Examples of eating disorders include pica, anorexia nervosa, bulimia nervosa, rumination disorder, avoidant/restrictive food intake disorder, and binge eating disorder. There remains a need in the art for improved compositions and methods for treating subjects using psilocybin. SUMMARY Psilocybin may provide numerous clinical benefits, such as benefits in neural plasticity and cognitive function (as measured using e.g., Cambridge Neuropsychological Test Automated Battery (CANTAB) tests ) with improvements in, for example, working memory and executive function, sustained attention, and episodic memory. These benefits have implications for psilocybin’s use in the treatment of various diseases, disorders, and conditions, including both psychiatric and neurological aspects thereof. In some embodiments, a method for treating one or more of anxiety disorders, eating disorders, and headache disorders, comprising administering to the subject an effective amount of psilocybin or an active metabolite thereof is disclosed herein. Provided herein is a method for treating an anxiety disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of psilocybin or an active metabolite thereof.
Load more

Recommended publications
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Treatment of Psychosis: 30 Years of Progress
    Journal of Clinical Pharmacy and Therapeutics (2006) 31, 523–534 REVIEW ARTICLE Treatment of psychosis: 30 years of progress I. R. De Oliveira* MD PhD andM.F.Juruena MD *Department of Neuropsychiatry, School of Medicine, Federal University of Bahia, Salvador, BA, Brazil and Department of Psychological Medicine, Institute of Psychiatry, King’s College, University of London, London, UK phrenia. Thirty years ago, psychiatrists had few SUMMARY neuroleptics available to them. These were all Background: Thirty years ago, psychiatrists had compounds, today known as conventional anti- only a few choices of old neuroleptics available to psychotics, and all were liable to cause severe extra them, currently defined as conventional or typical pyramidal side-effects (EPS). Nowadays, new antipsychotics, as a result schizophrenics had to treatments are more ambitious, aiming not only to suffer the severe extra pyramidal side effects. improve psychotic symptoms, but also quality of Nowadays, new treatments are more ambitious, life and social reinsertion. We briefly but critically aiming not only to improve psychotic symptoms, outline the advances in diagnosis and treatment but also quality of life and social reinsertion. Our of schizophrenia, from the mid 1970s up to the objective is to briefly but critically review the present. advances in the treatment of schizophrenia with antipsychotics in the past 30 years. We conclude DIAGNOSIS OF SCHIZOPHRENIA that conventional antipsychotics still have a place when just the cost of treatment, a key factor in Up until the early 1970s, schizophrenia diagnoses poor regions, is considered. The atypical anti- remained debatable. The lack of uniform diagnostic psychotic drugs are a class of agents that have criteria led to relative rates of schizophrenia being become the most widely used to treat a variety of very different, for example, in New York and psychoses because of their superiority with London, as demonstrated in an important study regard to extra pyramidal symptoms.
    [Show full text]
  • Dopamine D2 Receptor Occupancy by Perospirone: a Positron Emission Tomography Study in Patients with Schizophrenia and Healthy Subjects
    Psychopharmacology (2010) 209:285–290 DOI 10.1007/s00213-010-1783-1 ORIGINAL INVESTIGATION Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects Ryosuke Arakawa & Hiroshi Ito & Akihiro Takano & Masaki Okumura & Hidehiko Takahashi & Harumasa Takano & Yoshiro Okubo & Tetsuya Suhara Received: 3 September 2009 /Accepted: 18 January 2010 /Published online: 27 March 2010 # Springer-Verlag 2010 Abstract striatum of healthy subjects was 74.8% at 1.5 h, 60.1% at Rationale Perospirone is a novel second-generation antipsy- 8 h, and 31.9% at 25.5 h after administration. chotic drug with high affinity to dopamine D2 receptor and Conclusion Sixteen milligrams of perospirone caused over short half-life of plasma concentration. There has been no 70% dopamine D2 receptor occupancy near its peak level, investigation of dopamine D2 receptor occupancy in patients and then occupancy dropped to about half after 22 h. The with schizophrenia and the time course of occupancy by time courses of receptor occupancy and plasma concentra- antipsychotics with perospirone-like properties. tion were quite different. This single dosage may be Objective We investigated dopamine D2 receptor occupan- sufficient for the treatment of schizophrenia and might be cy by perospirone in patients with schizophrenia and the useful as a new dosing schedule choice. time course of occupancy in healthy subjects. Materials and methods Six patients with schizophrenia Keywords Dopamine D2 receptor occupancy. taking 16–48 mg/day of perospirone participated. Positron Perospirone . Positron emission tomography . emission tomography (PET) scans using [11C]FLB457 were Schizophrenia . Time course performed on each subject, and dopamine D2 receptor occupancies were calculated.
    [Show full text]
  • Final Program
    IPA-0716-539 Final Program #IPASanFran2016 ABOUT IPA Founded in 1982, the International Psychogeriatric Association (IPA) is a unique and diverse professional healthcare community promoting better geriatric mental health – across disciplines, across borders, and across geriatric issues. Psychiatrists, Scientists, Neurologists, Geriatricians, Primary Care Physicians, Epidemiologists, Nurses, Psychologists, Occupational Therapists, Social Workers and many other healthcare profession- als come to the IPA community from all over the world to discuss, learn, share and research information about behavioral and biological aspects of geriatric mental health. IPA Member Benefits • Subscription to International Psychogeriatrics, IPA’s multidisciplinary peer-reviewed journal published monthly • Subscription to the IPA Bulletin, IPA’s membership newsletter • Reduced rates and access to IPA congress and meetings • IPA Online – the IPA website – including the IPA Member Area with special features including access to fellow members and The IPA Complete Guide to Behavioral and Psychological Symptoms of Dementia (BPSD) • Participation in IPA Member Forums, IPA’s in-person and online groups which enable members to meet, communicate, and collaborate with IPA colleagues around the world. Groups include: Regional Initiative Forums (groups by geographic areas); Professional Discipline Forums (groups such as nurses, psychologists, primary care physicians, social workers, and occupational therapists); and Shared Interest Forums (interest groups including long term care, young onset dementia, testamentary capacity and others) IPA Board of Directors OFFICERS DIRECTORS EX OFFICIO Raimundo Mateos, President, Spain Sabine Bährer-Kohler, Switzerland Manabu Ikeda, Japan Mary Sano, President-Elect, United States David Conn, Canada IPA SECRETARIAT Huali Wang, Secretary, PR China Brian Draper, Australia Kate Filipiak, CAE, Executive Director Constantine G.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Comparing the Effectiveness of Mindfulness-Based Cognitive
    Special Issue INTERNATIONAL JOURNAL OF HUMANITIES AND May 2016 CULTURAL STUDIES ISSN 2356-5926 Comparing the effectiveness of mindfulness-based cognitive therapy and treatment based on acceptance and commitment therapy on reducing anxiety and depression in women with post-traumatic stress disorder caused by the accident Najaf Abad city of Esfahan Esmaeil Mardani Zadeh MA in Clinical Psychology [email protected] Elham Yousefi MA in Clinical Psychology [email protected] Atousa Khosravi Farsani MA in Psychology Atousa [email protected] Abstract Aims Secondary trauma is a psychological consequence of direct and prolonged contact with a post-traumatic stress disorder person. The purpose of this study was to Compare the effectiveness of mindfulness-based cognitive therapy (MBCT) and treatment based on acceptance and commitment therapy (ACT) on reducing anxiety and depression in women with post-traumatic stress disorder caused by the accident, with controlling the effect of depression, anxiety and stress. Methods: In this quasi-experimental research with pretest-posttest with control group design, 36 women of post-traumatic stress disorder caused by the accident referred to Modarress Psychiatric Hospital of Esfahan, Iran in 2015 were studied. The people who have attained high score on the secondary trauma test were randomly assigned to two experimental groups and one control group. The research instruments were a demographic questionnaire, questionnaire of secondary post-traumatic stress, and questionnaire of depression, anxiety and stress. The interventions (Mindfulness-based cognitive therapy and acceptance commitment therapy) in the experimental group were 8 weeks and once a week, the control group did not receive any training.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Dementia: Types, Stages and Sleep Disturbances
    DEMENTIA: TYPES, STAGES AND SLEEP DISTURBANCES Ericka L. Crouse, PharmD, BCPP, BCGP Associate Professor VCU School of Pharmacy Disclosures Dr. Crouse has nothing to disclose Objectives 1. Compare and contrast different types of dementia 2. Differentiate between stages of dementia and role of pharmacotherapy in each stage 3. List pros and cons of medications to treat sleep disturbances in dementia Pre-Assessment Question Which type of dementia is characterized by visual hallucinations especially of small animals and objects? A. Alzheimer’s B. Vascular C. Lewy-body D. Fronto-temporal Pre-Assessment Question Memantine is FDA indicated for which stage of Alzheimer’s disease? A. Mild cognitive impairment B. Mild/moderate C. Moderate/severe D. Only in combination with donepezil for mild/moderate Pre-Assessment Question Rapid-eye movement (REM) sleep behavior disorder is associated with which type of dementia? A. Alzheimer’s B. Vascular C. Lewy-body D. Fronto-temporal Pre-Assessment Question Which of the following is a risk associated with use of zolpidem in elderly patients? A. Falls with injury B. Decreased appetite C. Cognitive Impairment D. Anticholinergic effects Title TYPES OF DEMENTIA Change in Terminology DSM-IV DSM-5 • Dementia • Neurocognitive Disorder DSM = Diagnostic and Statistical Manual of Mental Disorders DSM-5 Am Psychiatric Assoc 2013 DSM-5 Criteria Evidence of a significant decline in cognitive function from previous level in ≥ 1 cognitive domain - Complex attention, executive function, learning and memory, language, perceptual-motor
    [Show full text]
  • Features of the Application of Art-Therapeutic and Gaming Technology Based on Folk Music in Rehabilitation and Socialization of Children with Health Limitations
    Scientific Foundation SPIROSKI, Skopje, Republic of Macedonia Open Access Macedonian Journal of Medical Sciences. 2020 Aug 15; 8(E):373-381. https://doi.org/10.3889/oamjms.2020.3588 eISSN: 1857-9655 Category: E - Public Health Section: Public Health Education and Training Features of the application of art-therapeutic and gaming technology based on folk music in rehabilitation and socialization of children with health limitations Natalia Ivanovna Anufrieva*, Aleksandr Vlavlenovich Kamenets, Marina Viktorovna Pereverzeva, Marina Gennadievna Kruglova Department of Sociology and Philosophy of Art, Russian State Social University, Wilhelm Pieck Street, 4/1, Moscow 129226, Russia Abstract Edited by: Ksenija Bogoeva-Kostovska AIM: The purpose of the work is to study the specifics and evaluate the effectiveness of the use of art-therapeutic Citation: Anufrieva NI, Kamenets AV, Pereverzeva MV, Kruglova MG. Features of the application of art- and gaming technologies based on musical folklore in the course of rehabilitation of children with health limitations. therapeutic and gaming technology based on folk music in rehabilitation and socialization of children with health MATERIALS AND METHODS: The socialization of such children depends largely on the characteristics of health, limitations. Open Access Maced J Med Sci. 2020 Aug 15; the principles of their training, and the effectiveness of the chosen methods. This justifies the need to analyze the 8(E):373-381. https://doi.org/10.3889/oamjms.2020.3588 *Correspondence: Natalia Ivanovna Anufrieva. practical experience and evaluate the results of efforts of specialists who deal with special children. Department of Sociology and Philosophy of Art, Russian State Social University, Wilhelm Pieck Street, 4/1, Moscow RESULTS: The results of the conducted psychological and pedagogical experiment on the use of art-therapeutic and 129226, Russia.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Supplementary Tables, Figures and Other Documents
    Clinical Relevance of a 16-Gene Pharmacogenetic Panel Test for Medication Management in a Cohort of 135 Patients David Niedrig1,2, Ali Rahmany1,3, Kai Heib4, Karl-Dietrich Hatz4, Katja Ludin5, Andrea M. Burden3, Markus Béchir6, Andreas Serra7, Stefan Russmann1,3,7,* 1 drugsafety.ch; Zurich, Switzerland 2 Hospital Pharmacy, Clinic Hirslanden Zurich; Zurich Switzerland 3 Swiss Federal Institute of Technology Zurich (ETHZ); Zurich, Switzerland 4 INTLAB AG; Uetikon am See, Switzerland 5 Labor Risch, Molecular Genetics; Berne, Switzerland 6 Center for Internal Medicine, Clinic Hirslanden Aarau; Aarau, Switzerland 7 Institute of Internal Medicine and Nephrology, Clinic Hirslanden Zurich; Zurich, Switzerland * Correspondence: [email protected]; Tel.: +41 (0)44 221 1003 Supplementary Tables, Figures and Other Documents Figure S1: Example of credit-card sized pharmacogenomic profile issued to patients 1 Table S2: SNPs analyzed by the 16-gene panel test Gene Allele rs number ABCB1 Haplotypes 1236-2677- rs1045642 ABCB1 3435 rs1128503 ABCB1 rs2032582 COMT Haplotypes 6269-4633- rs4633 COMT 4818-4680 rs4680 COMT rs4818 COMT rs6269 CYP1A2 *1C rs2069514 CYP1A2 *1F rs762551 CYP1A2 *1K rs12720461 CYP1A2 *7 rs56107638 CYP1A2 *11 rs72547513 CYP2B6 *6 rs3745274 CYP2B6 *18 rs28399499 CYP2C19 *2 rs4244285 CYP2C19 *3 rs4986893 CYP2C19 *4 rs28399504 CYP2C19 *5 rs56337013 CYP2C19 *6 rs72552267 CYP2C19 *7 rs72558186 CYP2C19 *8 rs41291556 CYP2C19 *17 rs12248560 CYP2C9 *2 rs1799853 CYP2C9 *3 rs1057910 CYP2C9 *4 rs56165452 CYP2C9 *5 rs28371686 CYP2C9 *6 rs9332131 CYP2C9
    [Show full text]
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
    [Show full text]